Stimulation of cholecystokinin-A receptors with GI181771X does not cause weight loss in overweight or obese patients.

• Cholecystokinin (CCK) decreases meal size through activation of CCK-A receptors on vagal afferents. We tested the hypothesis that the selective CCK-A agonist GI181771X induces weight loss in obese patients. Patients with body mass index > or = 30 or > or = 27 kg/m2 with concomitant risk factors were randomized to 24-week, double-blind treatment with different GI181771X doses or matching placebo together with a hypocaloric diet. The primary efficacy end point was the absolute change in body weight. To monitor pancreatic and gallbladder effects, patients underwent abdominal ultrasound and magnetic resonance imaging before and after treatment. We randomized 701 patients to double-blind treatment. GI181771X did not reduce body weight and had no effect on waist circumference or other cardiometabolic risk markers. Gastrointestinal side effects were more common with GI181771X than with placebo treatment, whereas hepatobiliary or pancreatic abnormalities did not occur. CCK-A by itself does not have a central role in long-term energy balance.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine (hsv//eng)

Nyckelord

Adult

Anti-Obesity Agents

adverse effects

therapeutic use

Benzodiazepines

adverse effects

therapeutic use

Caloric Restriction

Combined Modality Therapy

Double-Blind Method

Female

Gallbladder

drug effects

Humans

Liver

drug effects

Magnetic Resonance Imaging

Male

Middle Aged

Obesity

diet therapy

drug therapy

metabolism

pathology

Pancreas

drug effects

Receptor

Cholecystokinin A

agonists

metabolism

Time Factors

Treatment Outcome

Ultrasonography

Weight Loss

drug effects

Publikations- och innehållstyp

ref (ämneskategori)

art (ämneskategori)